UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(D)

of the Securities Exchange Act of 1934

 

July 8, 2019

Date of report (Date of earliest event reported)

 

 

Agile Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

Registrant’s telephone number, including area code (609) 683-1880

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 8, 2019, Scott M. Coiante, the Company’s Senior Vice President and Chief Financial Officer, informed the Company that he has accepted a position with a private company. Mr. Coiante will be departing the Company after the filing of the Company’s quarterly report on Form 10-Q for the period ending June 30, 2019.  After his departure, Mr. Coiante will be available to assist the Company to support a smooth transition of his roles and responsibilities through December 31, 2019. The Company has initiated a search for his successor. Joseph D’Urso, the Company’s Controller, will serve as the Company’s interim principal accounting and principal financial officer after Mr. Coiante leaves the Company while the Company completes its search for a permanent Chief Financial Officer.

 

Mr. Coiante’s decision to depart from the Company is solely for personal reasons and does not reflect any disagreement with the Company.  The Company thanked Mr. Coiante for his many contributions over nine years and for his willingness to continue to assist the Company to ensure a smooth transition.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Agile Therapeutics, Inc.
Dated: July 11, 2019	By:	/s/ Alfred Altomari
	Name: Alfred Altomari
	Title: Chairman and Chief Executive Officer

 

3